CBFB-MYH11阳性急性髓系白血病巩固化疗两周期后任何时间微小残留病<0.1%丢失或缺失提示预后不良
回顾性分析58例CBFB-MYH11阳性急性髓系白血病患者,中位随访29.8个月。未接受异基因造血干细胞移植的33例中,两周期巩固化疗后任何时间CBFB-MYH11/ABL>0.1%者复发率显著高于<0.1%者(61.9% vs 0%,P=0.001),3年无复发生存率和无事件生存率显著降低。
要点
- 两周期巩固化疗后任何时间CBFB-MYH11/ABL>0.1%者复发率61.9% vs <0.1%者0%(P=0.001)。
- 未移植患者中,CBFB-MYH11/ABL>0.1%者3年RFS 31.4% vs 100%(P=0.004)。
- 未移植者3年RFS和EFS低于移植者(31.4% vs 84.6%,P=0.000;31.4% vs 80.8%,P=0.001)。
核心结论
- CBFB-MYH11阳性AML患者两周期巩固化疗后任何时间CBFB-MYH11/ABL>0.1%者预后不良,异基因造血干细胞移植可改善其生存。
研究设计与样本
- 回顾性分析1525例急性髓系白血病患者中58例CBFB-MYH11阳性AML患者,其中16/58例有c-kit突变,中位随访29.8个月(范围4.8-74.4个月)。
主要发现
- 58例中25例(43.1%)接受异基因造血干细胞移植,其中10例有c-kit突变。
- 未移植的33例中,两周期巩固化疗后任何时间CBFB-MYH11/ABL>0.1%者复发率61.9% vs <0.1%者0%(P=0.001)。
- 未移植的33例中,CBFB-MYH11/ABL>0.1%者3年无复发生存率31.4% vs 100%(P=0.004),3年无事件生存率33.1% vs 100%(P=0.004)。
- 未移植者3年无复发生存率31.4% vs 移植者84.6%(P=0.000),3年无事件生存率31.4% vs 80.8%(P=0.001)。
临床怎么用
- 原文结论认为CBFB-MYH11阳性AML患者两周期巩固化疗后任何时间CBFB-MYH11/ABL>0.1%者预后不良,异基因造血干细胞移植可改善其生存。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
No consensus has been reached on the relationship between CBFB-MYH11 copies and prognosis. Of 1525 acute myeloid leukemia (AML) patients, 58 with CBFB-MYH11-positive AML (16/58 patients with c-kit mutation) were retrospectively analyzed with a median follow-up duration of 29.8 (range: 4.8-74.4) months. Of these, 25/58 (43.1%) patients underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT), 10 of whom had the c-kit mutation. Of the 33 patients who did not undergo allo-HSCT, recurrence in patients with CBFB-MYH11/ABL level >0.1% at any time after two consolidation cycles was significantly higher than in patients with CBFB-MYH11/ABL level <0.1% (61.9% vs. 0%, P = 0.001); further, the 3-year relapse-free survival (RFS; 31.4% vs. 100%, P = 0.004) and event-free survival (EFS; 33.1% vs. 100%, P = 0.004) were significantly decreased in patients with CBFB-MYH11/ABL level >0.1% at any time after two consolidation cycles. The 3-year RFS and EFS rates were lower in patients who did not receive allo-HSCT than in those who did (31.4% vs 84.6%, P = 0.000; 31.4% vs. 80.8%, P = 0.001). CBFB-MYH11-positive AML patients with CBFB-MYH11/ABL level >0.1% at any time after two cycles of consolidation had poor prognoses, and allo-HSCT could improve their survival.
引用
- Duan W, Liu X, Jia J, et al. The loss or absence of minimal residual disease of <0·1% at any time after two cycles of consolidation chemotherapy in CBFB-MYH11-positive acute myeloid leukaemia indicates poor prognosis. Br J Haematol. 2020. PMID: 32588434. doi:10.1111/bjh.16745
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。